{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:18Z","timestamp":1787027058289,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Meta-analysis of safety of Olaparib in the treatment of different indications.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The databases of PubMed, The Cochrane Library, EMbase, CNKI, WanFang Data and VIP were searched by computer to collect the research on the indications and the incidence of adverse reactions caused by Olaparib for different cancer types. The search time was from the establishment of the database to May 2022. After two researchers independently screened the literature, extracted the data and evaluated the bias risk included in the study, we used RevMan 5.4 software for meta-analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 14 studies were included, with a total sample size of 5119 cases. By meta-analysis, the adverse reactions of Olaparib in the treatment of pancreatic cancer, breast cancer and ovarian cancer were compared. In adverse reactions of any grade, the results showed that fatigue (RR = 1.58, 95% CI [1.20\u20132.07],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001) was the most serious in the treatment of pancreatic cancer with Olaparib. Anemia (RR = 2.94, 95% CI [1.97\u20134.39],\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.00001), neutropenia (RR = 1.37, 95% CI [0.80\u20132.33],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.25), nausea (RR = 1.93, 95% CI [1.61\u20132.32],\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.00001) and vomiting (RR = 1.96, 95% CI [1.59\u20132.41],\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.00001) were the most severe in ovarian cancer. In adverse reactions of grade 3 or above, fatigue (RR = 3.44, 95% CI [1.48\u20137.98],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004) and vomiting (RR = 1.09, 95% CI [0.42\u20132.81],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.86) were the most serious adverse reactions in the treatment of breast cancer with Olaparib. Anemia (RR = 9.74, 95% CI [2.75\u201334.47],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0004), neutropenia (RR = 1.33, 95% CI [0.87\u20132.02],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.19) and nausea (RR = 2.94, 95% CI [1.18\u20137.32],\n                    <jats:italic>p<\/jats:italic>\n                    = 0.02) were the most severe in ovarian cancer. In addition, the incidence of decreased white blood cell count and hepatotoxicity in the treatment of breast cancer, and the incidence of decreased platelet count, constipation and abdominal pain in the treatment of ovarian cancer were higher than those in pancreatic cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Current evidence showed that the risk of adverse reactions of Olaparib in the treatment of different indications is different, and specific analysis and treatment should be carried out for different cancer types. Due to the limitation of the quantity and quality of the included studies, the above conclusions need to be verified by more high-quality studies.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.968163","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:21:16Z","timestamp":1657689676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of Adverse Reactions Caused by Olaparib for Different Indications"],"prefix":"10.3389","volume":"13","author":[{"given":"Yujing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdu581","article-title":"Phase I Study of Olaparib Plus Gemcitabine in Patients with Advanced Solid Tumours and Comparison with Gemcitabine Alone in Patients with Locally Advanced\/Metastatic Pancreatic Cancer","volume":"26","author":"Bendell","year":"2015","journal-title":"Ann. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific Killing of BRCA2-Deficient Tumours with Inhibitors of poly(ADP-Ribose) Polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"Parp-2 Is Required to Maintain Hematopoiesis Following Sublethal \u03b3-irradiation in Mice","volume":"122","author":"Farr\u00e9s","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant Paclitaxel\/olaparib in Comparison to Paclitaxel\/carboplatinum in Patients with HER2-Negative Breast Cancer and Homologous Recombination Deficiency (GeparOLA Study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdz406","article-title":"Health-related Quality of Life in Patients with a Germline BRCA Mutation and Metastatic Pancreatic Cancer Receiving Maintenance Olaparib","volume":"30","author":"Hammel","year":"2019","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8753","DOI":"10.1038\/s41598-020-63033-4","article-title":"Olaparib Monotherapy for Asian Patients with a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer: OlympiAD Randomized Trial Subgroup Analysis","volume":"10","author":"Im","year":"2020","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4081\/oncol.2019.425","article-title":"Efficacy and Safety Profiles of Programmed Cell Death-1\/programmed Cell Death Ligand-1 Inhibitors in the Treatment of Triple-Negative Breast Cancer: A Comprehensive Systematic Review","volume":"13","author":"Lazarus","year":"2019","journal-title":"Oncol. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage Wisely: Poly (ADP-Ribose) Polymerase Inhibitor (PARPi) Treatment and Adverse Events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib Combined with Chemotherapy for Recurrent Platinum-Sensitive Ovarian Cancer: a Randomised Phase 2 Trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus Nonplatinum Chemotherapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1\/2 Mutation (SOLO3): A Randomized Phase III Trial","volume":"38","author":"Penson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): a Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1056\/NEJMx170012","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD Final Overall Survival and Tolerability Results: Olaparib versus Chemotherapy Treatment of Physician's Choice in Patients with a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.968163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:21:18Z","timestamp":1657689678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.968163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":23,"alternative-id":["10.3389\/fphar.2022.968163"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.968163","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"article-number":"968163"}}